

Review

Open Access

Role of the Fas/FasL Pathway in HIV or SIV Disease

Bhawna Poonia, C David Pauza and Maria S Salvato*

Address: Institute of Human Virology, University of Maryland, School of Medicine, 725 W. Lombard Street, Baltimore, MD 21201

Email: Bhawna Poonia - bpoonia@ihv.umaryland.edu; C David Pauza - cdpauza@ihv.umaryland.edu;

Maria S Salvato* - msalvato@ihv.umaryland.edu

* Corresponding author

Published: 15 October 2009

Received: 21 July 2009

Retrovirology 2009, 6:91 doi:10.1186/1742-4690-6-91

Accepted: 15 October 2009

This article is available from: <http://www.retrovirology.com/content/6/1/91>

© 2009 Poonia et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Human immunodeficiency virus disease involves progressive destruction of host immunity leading to opportunistic infections and increased rates for malignancies. Quantitative depletion of immune cell subsets and accruing defects in cell effector functions are together responsible for immunodeficiency. The broad impact of HIV reflects a similarly broad spectrum of affected cells including subsets that do not express viral receptors or support viral replication. Indirect cell killing, the destruction of uninfected cells, is one important mechanism due partly to activation of the Fas/FasL system for cell death. This death-signaling pathway is induced during HIV disease and contributes significantly to viral pathogenesis and disease.

Background

Changes in CD4 cell count and viral RNA burden are common markers for HIV disease progression. However, evidence has existed for several years that many patients with HIV disease experience a broad loss of leukocyte subsets without an apparent preference for depleting CD4 T cells [1-3]. Effects on cell types other than CD4 T cells were documented in macaques after showing substantial B cell loss during acute SIV infection [4], and in humans by showing depletion of $\gamma\delta$ T cells [5] that are CD4 negative. Many other examples confirmed that the profound impact of HIV on "non-CD4" leukocyte populations depends on indirect mechanisms, as opposed to direct cell killing that occurs when HIV or SIV infects and destroys susceptible CD4+ cells. Surely, uninfected CD4+ cells can also be destroyed by indirect mechanisms if they escape direct infection. Since both direct and indirect mechanisms are driven by viral burden, it has been difficult to distinguish their contributions to CD4+ T cell depletion and progressing disease. This technical obstacle has

blocked efforts to explore new therapies that target indirect mechanisms for cell depletion in HIV disease.

Besides depleting immune cells, HIV infection is characterized by defects in cell effector functions. Low cytotoxicity among circulating HIV-specific CD8+ T cells has been attributed to loss of CD3-complex zeta chains [6] and T cell exhaustion was linked to high levels of PD-1 or CTLA-4 on the surface of T cells [7,8]. During chronic HIV infection, immune dysfunction can also result from interactions with regulatory T cells (Tregs) [9,10] that are exported to the periphery during high thymic turnover [11]. Ultimately, Tregs contribute to immune suppression and to cell death via the Fas/FasL apoptotic pathways (Fig. 1).

Mechanisms of indirect cell depletion in HIV infection

Despite overwhelming evidence for indirect cell depletion, little is known about how it occurs *in vivo*. Cell loss is accelerated during elevated viremia and a broad recov-




Figure 1

Major mechanisms of leukocyte cell loss in AIDS. Two models for cell death in AIDS are the direct and indirect killing of leukocytes during disease progression. Direct killing, or killing of virus-infected cells, is presumed to be virus-mediated or to occur via immune surveillance of virus-infected cells, most often by killer T cells. The virus-infected cells are predominately memory T cells with the phenotype CD4+CD45RA- or CD4+CD45RA+Fas and are primarily killed by cytotoxic T cells in a Fas-independent manner [52]. Indirect cell death, or killing of uninfected "bystander" cells, has also been documented *in vivo*. All leukocytes, including uninfected bystander cells, can be activated, with up-regulation of Fas/FasL and other death mediators, after contact with HIV-infected cells or HIV antigens such as soluble *tat*, *gp120*, *vpr*, and *nef* [20,24,38,39,49]. Thus HIV gene expression contributes to both direct and indirect killing mechanisms. Contact with death ligands like FasL causes apoptosis of activated cells through Fas/FasL signaling. Tregs are major effectors of bystander killing. The finding that HIV+ cells are less susceptible to Fas/FasL killing means that HIV+ cells become enriched when Fas-mediated apoptosis is the major death pathway.

ery of leukocytes attends highly active antiretroviral therapy (HAART) [12]. Some of these changes may be related to release of sequestered lymphocytes from secondary lymphoid tissues [13] as viral antigen declines during therapy. HIV effects on bone marrow, thymus, and hematopoietic stem cells were also proposed as causes for general leukocyte loss [14]. While HIV does indeed infect and

alter bone marrow and thymus, the kinetics for cell loss during acute infection, the rates for recovery during HAART and the durable repertoire defects in T and B cell subsets after HAART [15,16] argue that these dynamic changes occur within mature populations without an overwhelming impact from declining stem cell output. With large expansions and contractions of mature cell

populations, declining stem cells may have a lesser impact on leukocyte depletion in AIDS.

A process described as "chronic immune activation" or "hyperactivation" occurs during HIV disease and is accompanied by higher expression of TNF superfamily ligands and their receptors, e. g. Fas/FasL and TRAIL-DR5 [17-20]. Chronic activation coincides with "activation induced cell death" (AICD), a term coined initially to describe cell loss occurring when lymphocytes are activated by viral antigen in the absence of appropriate costimulation. AICD connects viral gene expression to general lymphocyte destruction, ultimately resulting in reduced immune protection from HIV. Now it is known that both viral and host products can activate lymphocytes and induce death receptor expression. Secreted HIV Tat protein up-regulates FasL and TRAIL in T cells or macrophages, which in turn, induce apoptosis in bystander cells thereby providing a mechanism for cell death among uninfected cells [21-23]. In HIV disease, both antigen-specific and polyclonal activation have been observed [17,24,25]. This pan-activation sensitizes lymphocytes to apoptotic cell death that occurs when the death ligand, usually cell-associated, contacts a cell that is expressing death receptors.

Early investigators [26] proposed apoptotic death as an important contributor to CD4 T cell depletion. They observed that triggering through the T cell receptor failed to induce proliferation of PBMC from HIV+ asymptomatic donors; instead, CD4 cells in these cultures had features consistent with Fas-mediated apoptosis [27]. We confirmed this result in SIV-infected macaques [28]. Alternatively, signaling through the T cell receptor [29] can activate the mitochondrial pathway for apoptosis, distinct from the Fas-triggered caspase-8 death pathway [30]. Both pathways are generally invoked in AICD (Figure 1). Since antigen-specific memory T cells are more likely to express Fas, cell killing appears tied to antigen specificity. Both caspase 8 and mitochondrial apoptosis mechanisms tend to delete immune cells that respond to antigen. Preferential apoptotic cell death among antigen-activated T cells could account for the lack of immune control over opportunistic pathogens and an insufficiency of viral immunity that fails to prevent viral persistence or progressing disease. Once the host environment is "set," and after viremia triggers higher expression of FasL, every encounter with antigen has the potential to drive cell depletion among all lymphocyte compartments.

Role of Fas/FasL mediated cell death in HIV/SIV infections

Apoptosis is observed consistently among uninfected cells in SIV+ macaques or HIV+ humans [31]. Chronic immune activation drives cells into apoptosis [32] possibly involving Fas/FasL interactions [33], and reflects an

exaggeration of the normal processes for homeostatic cell regulation during HIV disease [34]. The roles of assassin and victim are not always clear in these interactions. Activated CD4+ T cells can express FasL and become the effectors of cell death including the destruction of resting B cells [35], even as they also become targets for cell killing and display high rates for apoptosis during disease.

Many studies have explored the mechanisms connecting HIV/SIV antigen expression and apoptotic cell death. Human macrophages express FasL after exposure to HIV [36], creating a link between antigen presentation and Fas/FasL-mediated apoptosis. HIV up-regulates FasL in CD4 T cells [37,38] after they are exposed to soluble Tat, gp120 [22] or Nef proteins [39]. Higher levels of FasL, both cell-associated and in plasma, and Fas were observed in specimens from HIV+ patients whose PBMC were especially susceptible to Fas-mediated cell death *in vitro* [40]. Cross-linking of CD4 by gp120 complexes or viral particles increased the susceptibility to apoptosis triggered by FasL or TNF- α [41,42].

The patterns of CD4 T cell depletion appear to be antigen-specific, as perturbation of the CD4 receptor repertoire is significantly associated with higher plasma viremia [43]. This can be explained by an AICD mechanism or by virus infection of antigen-activated cells as we proposed [44]. Less data are available to show whether CD8+ T cell or B cell loss during HIV infection is antigen-specific, although altered receptor repertoire have been reported in both cases [45-47]. The $\gamma\delta$ T cell population shows a specific pattern of depletion in HIV disease [5], losing the critical V γ 2-J γ 1.2+ subset that is required for pathogen and tumor cell responses but few cells express CD4 and $\gamma\delta$ T cells do not support HIV replication. To the extent that antigen stimulation is related to cell depletion, AICD may be invoked as a mechanism for $\gamma\delta$ T cell killing. Thus, AICD is a mechanism that potentially links antigen stimulation with expression of death ligand receptors, leading to specific cell depletion.

Neuronal cells that are depleted during chronic HIV infection comprise an important example of bystander depletion since they are not infected by HIV. Neuronal cell loss has been attributed to interaction with viral proteins such as gp120, vpr, nef, and tat, and to soluble neurotoxic factors released by infected macrophages [48]. The primary mechanism for neuronal depletion is apoptosis via extrinsic Fas-related death receptors or intrinsic mitochondrial pathways [48]. The fate of neuronal cells during AIDS is reminiscent of the cell culture studies mentioned previously that documented apoptotic destruction of uninfected cells upon exposure to viral proteins [20,24,38,39,49].

Broadly acting immune stimulation during HIV or SIV infection especially implicates the Fas death pathway since activated T or B cells express Fas. Acute SIV infection triggers rapid increases in Fas and FasL expression in peripheral blood [50] as well as in thymus and other lymphoid tissues [51]. During acute SIV infection, most T cells express Fas [52] and there is abundant local expression of FasL among intestinal lymphocytes [53]. Ablation of intestinal lamina propria CD4+ cells during SIV infection can be attributed in part, to the Fas/FasL mediated apoptotic pathway but it is controversial whether apoptotic death of uninfected cells exceeds virus-mediated killing of infected cells. Detailed studies of viral burden and the rising proportion of SIV+ intestinal T cells argued that direct depletion of infected cells accounts for the rapid cell loss [52] without the need to invoke apoptotic killing of uninfected cells. These investigators stated that up to 60% of all memory T cells were infected but that those cells were lost within 4 days. They defined memory CD4+ cells as those that were CD45RA- or CD45RA+CD95+, meaning that Fas+ (CD95+) cells that are highly susceptible to apoptosis are included. Circulating lymphocytes and lymphocytes from lymph nodes and mucosa were sampled, but lymphocytes were not sampled from the spleen or liver, for example, so it is impossible to rule out margination as an explanation for lymphocyte loss. There is no way to determine from the experimental design, whether infected cells are being depleted faster than uninfected cells.

Another recent publication from Mattapallil's laboratory notes that early mucosal HIV/SIV infection (2-4 days after inoculation) demonstrates high levels of infected CD4+ Th-17 T cells that are depleted during the course of infection [54]. Th-17 cells are proinflammatory effectors of antiviral immunity and are commonly suppressed by Treg, most likely being depleted via the Fas pathway. Once again it is not clear whether depletion is due to cell death in the category of direct depletion of virus-infected cells or indirect depletion of uninfected bystander cells. It is highly improbable that any one mechanism will explain all events in AIDS pathogenesis, so we expect both mechanisms to be operating during infection.

Several important studies have implicated apoptosis among uninfected cells as a major mechanism for leukocyte depletion. Fas ligation was a probable cause for apoptosis in T cells from SIV infected macaques [55]. However, caspase-independent pathways for T cell apoptosis were thought to drive cell death in other SIV infection studies [56]. Cell loss, especially in gut-associated lymphoid tissues, likely occurs by multiple mechanisms and we would expect depletion of both CD4+ and CD4- cell subsets at these loci of intense viral replication.

A recent publication described gene expression profiles at three stages of HIV infection: acute, chronic, and AIDS [57]. The acute stage had high levels of FasL mRNA expression that were diminished during the chronic stage. This observation coincides with earlier published studies showing a high level of PBMC-susceptibility to AICD during the acute stage of SIV infection, and this susceptibility subsides during the chronic stage [58].

Curiously, infected cells are more resistant to apoptosis than uninfected cells [23,59]. The apoptosis resistance in persistently infected lymphoid and monocytic cells was shown to be independent of active viral production and involved a modulation of the mitochondrial pathway [60]. A consequence is that indirect cell killing through apoptotic mechanisms like Fas/FasL, will destroy activated, uninfected cells while sparing the fraction of infected cells. Such a process will tend to increase the proportion of infected cells and diminish the proportion of uninfected cells in a tissue heavily burdened by SIV or HIV. Perhaps this mechanism contributes to the very high proportions of infected cells noted in macaque intestinal tissues after SIV infection [52] and may help to reconcile apparent differences between direct and indirect cell depletion models.

Substantial data have been accumulated on HIV induction of Fas or FasL, the susceptibility of PBMC from HIV patients to apoptotic cell death and the reversal of these conditions by HAART. When viremia was suppressed by effective HAART, CD4 cells in PBMC had significantly reduced apoptosis levels that correlated with increasing CD4 counts in blood even though lymphoid tissue FasL levels were unchanged [61,62]. Similar findings have been reported for SIV infections. However, the problem remains that susceptibility to apoptosis, measured *in vitro*, rises and falls with changes in viremia, making it difficult to separate direct from indirect killing mechanisms in terms of their relative contributions to disease progression. In murine systems, these problems are addressed readily by the use of knock-out mutations eliminating Fas, FasL or both molecules. For AIDS-related questions, the initial studies are done most appropriately in nonhuman primates using SIV or SHIV to establish persistent infection and then applying interventions to modulate the Fas/FasL pathway.

Using a recombinant humanized anti-FasL monoclonal antibody [63] we developed a protocol for treating rhesus macaques to interrupt the Fas/FasL system. Animals received a total of 5 injections of anti-FasL given once per week beginning 2 weeks before SIV-inoculation and finishing 2 weeks after virus inoculation. The pilot study showed no effect of anti-FasL on plasma viremia, but found increased virus-specific immunity and delayed dis-

ease among treated animals [64]. A larger study using immunized macaques indicated that anti-FasL treatment preserved memory T cells, antigen responses after SIV infection, and was associated with decreased levels of Treg cells [65]. In the two interventional studies, anti-FasL delivered before and during the acute infection had a durable effect on immune status and disease many months after treatment stopped. These changes were not reflected in vRNA levels that were similar among treatment and control groups, but were detected in the composition and activity of other T cell populations. This means that uninfected effector cells must have been preserved by the treatment.

Another indication of the importance for indirect cell killing comes from studies of "naturally-infected" macaques i.e., sooty mangabeys infected with SIVsmm that maintain plasma viremia, do not show high susceptibility to *in vitro* apoptosis among PBMC and remain disease-free [66]. Here, apoptosis and immune activation were low and animals did not develop disease despite chronic viremia. The observation of preserved CD4 T lymphocytes with regenerative capacity in spite of high viremia, suggests that virus alone cannot explain the massive loss of CD4 lymphocytes that occurs in pathogenic SIV and HIV infections [67] and indirect cell killing mechanisms may be important.

We reported [68] that half of 56 macaques tested showed high levels of MHC-unrestricted cytolysis prior to SIV inoculation and that animals from this group were all among the rapid progressors. Subsequently, we found that MHC-unrestricted cytolysis involves the Fas/FasL pathway [64] and rapid progressors had higher baseline levels of cell killing through this pathway. In corroboration of these findings, high levels of lymph node cell apoptosis during acute SIV infection also predict that animals will become rapid progressors [69].

Reports showing lower levels of indirect cell killing/apoptosis among naturally-infected macaques despite similar viremia [64,67,70], the correlation between apoptosis and rapid progression [69] and intervention studies showing disease-sparing after brief treatment with monoclonal antibody against FasL [64,65] attest to strong relationships between apoptotic killing of uninfected cells and pathogenesis. The *in vitro* and tissue studies on HIV agree with these findings. Disagreements remain about the mechanisms for cell death, the roles for viral proteins and the relative importance of Fas versus non-Fas death pathways. In addition to direct infection and cell destruction by viral cytopathic effects or antigen-specific cytotoxicity, indirect cell killing mechanisms have broad impact on host immune capacity and are important in the pathogenesis of HIV/AIDS.

Significance of indirect cell killing for HIV vaccine/therapeutics design

Knowing the role for uninfected bystander cell killing in disease has not resolved the challenge of applying this information to treating HIV in man. An anti-Fas treatment during acute infection would be difficult to deliver. Since it may not modulate vRNA, the main marker for HIV therapy, lengthy studies would be needed to document treatment effects. The use of anti-retroviral therapy during this time would also obscure the impact of blocking FasL, but lowering viral burden during the critical time of acute infection may spare cells from indirect depletion. A combination of anti-FasL plus active immunization during interrupted HAART is conceivable, but unlikely to be pursued given the treatment choices and durable virus suppression achievable with available drugs. The most likely application of this knowledge may come in the evaluation of prophylactic or therapeutic vaccines. If we define viral proteins that are responsible for inducing bystander cell killing or identify particular motifs within these proteins that trigger killing mechanisms, vaccine-elicited antibodies may block these effects and preserve immunity even if vRNA levels appear unchanged. For example, gp41 peptide was shown to induce Nkp44L on CD4+ T cells during HIV infection, making them highly susceptible to NK lysis. Immunizing against this peptide reduced ligand expression on CD4 lymphocytes and decreased apoptosis rates in SHIV-infected macaques [71] thereby indicating its role in promoting bystander cell killing. Careful evaluation of cellular apoptosis and tissue levels of Fas or FasL will be important to evaluate vaccine trials. FasL bearing CD4 lymphocytes were shown recently to kill antigen expressing cells following plasmid immunization, resulting in both lower antigen expression and subsequent decreases in antigen-specific cellular immunity [72]. Such mechanisms may impact other biological therapies in HIV/AIDS and appropriate inhibitors of Fas/FasL may be required to properly implement new interventions.

Conclusion

HIV infection depletes a broad profile of leukocyte subsets including many that do not express CD4 and are not susceptible to direct virus infection. Models for the loss of non-CD4+ subsets including activation-induced cell death, explain the antigen-specific pattern of cell loss and frequently invoke Fas/FasL interactions as a principal mediator of cell death. The role for FasL was tested in the SIV/macaque model for AIDS using recombinant humanized monoclonal antibodies to neutralize this cell death ligand. Treated macaques modulated SIV disease and increased virus-specific immunity without consistent reduction in vRNA burden. The status of animals treated with anti-FasL was similar to natural SIVsmm infection of sooty mangabeys that have no overt disease despite high

chronic viremia and show minimal apoptosis and immune hyperactivation.

The Fas/FasL death pathway is an important component of SIV or HIV disease. Whether this pathway for cell death is driven by viral proteins, virus particles or induced host factors remains unknown, although compelling examples of each exist in literature. The capacity to control activation of this cell death pathway may be important for the ultimate success of preventive vaccine strategies. The magnitude and duration of protective immunity, once viral exposure has occurred, are key to controlling infection and disease. Cell death pathways like Fas/FasL may be exploited by HIV to reduce the level of protective immunity and to establish a persistent infection with progressing disease. There is a continuing need to understand these mechanisms and develop effective interventions to improve the impact of antiretroviral therapy.

References

- Ho J, Moir S, Malaspina A, Howell ML, Wang W, DiPoto AC, O'Shea MA, Roby GA, Kwan R, Mican JM, et al: **Two overrepresented B cell populations in HIV-infected individuals undergo apoptosis by different mechanisms.** *Proc Natl Acad Sci USA* 2006, **103**:19436-41.
- Mela CM, Steel A, Lindsay J, Gazzard BG, Gotch FM, Goodier MR: **Depletion of natural killer cells in the colonic lamina propria of viraemic HIV-1-infected individuals.** *AIDS* 2007, **21**:2177-82.
- Moir S, Fauci AS: **B cells in HIV infection and disease.** *Nat Rev Immunol* 2009, **9**:235-45.
- Dykhuizen M, Mitchen JL, Montefiori DC, Thomson J, Acker L, Lardy H, Pauza CD: **Determinants of disease in the simian immunodeficiency virus-infected rhesus macaque: characterizing animals with low antibody responses and rapid progression.** *J Gen Virol* 1998, **79**(Pt 10):2461-7.
- Enders PJ, Yin C, Martini F, Evans PS, Propp N, Poccia F, Pauza CD: **HIV-mediated gammadelta T cell depletion is specific for Vgamma2+ cells expressing the Jgamma1.2 segment.** *AIDS Res Hum Retroviruses* 2003, **19**:21-9.
- Trimble LA, Lieberman J: **Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3 zeta, the signaling chain of the T-cell receptor complex.** *Blood* 1998, **91**:585-94.
- Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EV, Miller JD, Leslie AJ, DePierres C, et al: **PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.** *Nature* 2006, **443**:350-4.
- Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EV, Miura T, Palmer S, Brockman M, Rathod A, Piechocka-Trocha A, et al: **Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction.** *Nat Immunol* 2007, **8**:1246-54.
- Amarnath S, Dong L, Li J, Wu Y, Chen W: **Endogenous TGF-beta activation by reactive oxygen species is key to Foxp3 induction in TCR-stimulated and HIV-1-infected human CD4+CD25- T cells.** *Retrovirology* 2007, **4**:57.
- Cao W, Jamieson BD, Hultin LE, Hultin PM, Detels R: **Regulatory T cell expansion and immune activation during untreated HIV type 1 infection are associated with disease progression.** *AIDS Res Hum Retroviruses* 2009, **25**:183-91.
- Kolte L, Gaardbo JC, Skogstrand K, Ryder LP, Ersboll AK, Nielsen SD: **Increased levels of regulatory T cells (Tregs) in human immunodeficiency virus-infected patients after 5 years of highly active anti-retroviral therapy may be due to increased thymic production of naive Tregs.** *Clin Exp Immunol* 2009, **155**:44-52.
- Robbins GK, Spritzler JG, Chan ES, Asmuth DM, Gandhi RT, Rodriguez BA, Skowron G, Skolnik PR, Shafer RW, Pollard RB: **Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384.** *Clin Infect Dis* 2009, **48**:350-61.
- Bucy RP, Hockett RD, Derdeyn CA, Saag MS, Squires K, Sillers M, Mitsuyasu RT, Kilby JM: **Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues.** *J Clin Invest* 1999, **103**:1391-8.
- Brown KN, Wijewardana V, Liu X, Barratt-Boyes SM: **Rapid influx and death of plasmacytoid dendritic cells in lymph nodes mediate depletion in acute simian immunodeficiency virus infection.** *PLoS Pathog* 2009, **5**:e1000413.
- Aiuti F, Mezzaroma I: **Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART.** *AIDS Rev* 2006, **8**:88-97.
- Badolato R: **Immunological nonresponse to highly active antiretroviral therapy in HIV-infected subjects: is the bone marrow impairment causing CD4 lymphopenia?** *Clin Infect Dis* 2008, **46**:1911-2.
- Gasper-Smith N, Crossman DM, Whitesides JF, Mensali N, Ottinger JS, Plonk SG, Moody MA, Ferrari G, Weinhold KJ, Miller SE, et al: **Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design.** *J Virol* 2008, **82**:7700-10.
- Herbeuval JP, Nilsson J, Boasso A, Hardy AW, Vaccari M, Cecchinato V, Valeri V, Franchini G, Andersson J, Shearer GM: **HAART reduces death ligand but not death receptors in lymphoid tissue of HIV-infected patients and simian immunodeficiency virus-infected macaques.** *AIDS* 2009, **23**:35-40.
- Miura Y, Koyanagi Y: **Death ligand-mediated apoptosis in HIV infection.** *Rev Med Virol* 2005, **15**:169-78.
- Yang Y, Tikhonov I, Ruckwardt TJ, Djavani M, Zapata JC, Pauza CD, Salvato MS: **Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism.** *J Virol* 2003, **77**:6700-8.
- Campbell GR, Pasquier E, Watkins J, Bourgarel-Rey V, Peyrot V, Esquieu D, Barbier P, de Mareuil J, Braguer D, Kaleebu P, et al: **The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis.** *J Biol Chem* 2004, **279**:48197-204.
- Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H, Debatin KM, Krammer PH: **Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120.** *Nature* 1995, **375**:497-500.
- Zhang M, Li X, Pang X, Ding L, Wood O, Clouse KA, Hewlett I, Dayton AL: **Identification of a potential HIV-induced source of bystander-mediated apoptosis in T-cells: Upregulation of TRAIL in primary Human Macrophages by HIV-1 Tat.** *J Biomed Sci* 2001, **8**:290-96.
- Lum JJ, Schnepf DJ, Badley AD: **Acquired T-cell sensitivity to TRAIL mediated killing during HIV infection is regulated by CXCR4-gp120 interactions.** *AIDS* 2005, **19**:1125-33.
- Muthumani K, Choo AY, Hwang DS, Premkumar A, Dayes NS, Harris C, Green DR, Wadsworth SA, Siekierka JJ, Weiner DB: **HIV-1 Nef-induced FasL induction and bystander killing requires p38 MAPK activation.** *Blood* 2005, **106**:2059-68.
- Terai C, Kornbluth RS, Pauza CD, Richman DD, Carson DA: **Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1.** *J Clin Invest* 1991, **87**:1710-5.
- Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC: **Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals.** *J Exp Med* 1992:331-40.
- Wallace M, Pauza CD, Salvato MS: **Macaque models for early immunosuppression and T cell loss during acute immunodeficiency virus infections.** *J Biol Regul Homeost Agents* 2001, **15**:304-7.
- Gougeon ML, Colizzi V, Dalglish A, Montagnier L: **New concepts in AIDS pathogenesis.** *AIDS Res Hum Retroviruses* 1993, **9**:287-9.
- Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH: **Fas ligand mediates activation-induced cell death in human T lymphocytes.** *J Exp Med* 1995, **181**:71-7.
- Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba TW, Ruprecht RM, Kupfer A: **Apoptosis occurs**

- predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. *Nat Med* 1995, **1**:129-34.
32. Gougeon ML: **Chronic activation of the immune system in HIV infection: contribution to T cell apoptosis and V beta selective T cell energy.** *Curr Top Microbiol Immunol* 1995, **200**:177-93.
 33. Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A: **Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.** *Nature* 1995, **373**:444-8.
 34. Lynch DH, Ramsdell F, Alderson MR: **Fas and FasL in the homeostatic regulation of immune responses.** *Immunol Today* 1995, **16**:569-74.
 35. Rothstein TL, Wang JK, Panka DJ, Foote LC, Wang Z, Stanger B, Cui H, Ju ST, Marshak-Rothstein A: **Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells.** *Nature* 1995, **374**:163-5.
 36. Badley AD, McElhinny JA, Leibson PJ, Lynch DH, Alderson MR, Paya CV: **Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes.** *J Virol* 1996, **70**:199-206.
 37. Ji J, Cloyd MW: **HIV-1 binding to CD4 on CD4+CD25+ regulatory T cells enhances their suppressive function and induces them to home to, and accumulate in, peripheral and mucosal lymphoid tissues: an additional mechanism of immunosuppression.** *Int Immunol* 2009, **21**:283-94.
 38. Mitra D, Steiner M, Lynch DH, Staiano-Coico L, Laurence J: **HIV-1 upregulates Fas ligand expression in CD4+ T cells in vitro and in vivo: association with Fas-mediated apoptosis and modulation by aurointra-carboxylic acid.** *Immunology* 1996, **87**:581-5.
 39. Xu XN, Screaton GR, Gotch FM, Dong T, Tan R, Almond N, Walker B, Stebbings R, Kent K, Nagata S, et al.: **Evasion of cytotoxic T lymphocyte (CTL) responses by nef-dependent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells.** *J Exp Med* 1997, **186**:7-16.
 40. Sloan EM, Young NS, Kumar P, Weichold FF, Sato T, Maciejewski JP: **Role of Fas ligand and receptor in the mechanism of T-cell depletion in acquired immunodeficiency syndrome: effect on CD4+ lymphocyte depletion and human immunodeficiency virus replication.** *Blood* 1997, **89**:1357-63.
 41. Algeciras A, Dockrell DH, Lynch DH, Paya CV: **CD4 regulates susceptibility to Fas ligand- and tumor necrosis factor-mediated apoptosis.** *J Exp Med* 1998, **187**:711-20.
 42. Boirivant M, Viora M, Giordani L, Luzzati AL, Pronio AM, Montesani C, Pugliese O: **HIV-1 gp120 accelerates Fas-mediated activation-induced human lamina propria T cell apoptosis.** *J Clin Immunol* 1998, **18**:39-47.
 43. Malhotra U, Huntsberry C, Holte S, Lee J, Corey L, McElrath MJ: **CD4+ T cell receptor repertoire perturbations in HIV-1 infection: association with plasma viremia and disease progression.** *Clin Immunol* 2006, **119**:95-102.
 44. Pauza CD: **HIV Persistence in Monocytes Leads to Pathogenesis and AIDS.** *Cellular Immunology* 1988, **112**:414-424.
 45. Kharbanda M, McCloskey TW, Pahwa R, Sun M, Pahwa S: **Alterations in T-cell receptor Vbeta repertoire of CD4 and CD8 T lymphocytes in human immunodeficiency virus-infected children.** *Clin Diagn Lab Immunol* 2003, **10**:53-8.
 46. Ren GL, Chen JP, Jia MM, Kou ZC, Liu S, Ma PF, Shao YM, Hong KX: **[T cell receptor diversity of CD8(+) T lymphocytes and its association with viral load in individuals with HIV-1 infection.]** *Zhonghua Yu Fang Yi Xue Za Zhi* 2009, **43**:404-8.
 47. Viau M, Veas F, Zouali M: **Direct impact of inactivated HIV-1 virions on B lymphocyte subsets.** *Mol Immunol* 2007, **44**:2124-34.
 48. Chen W, Tang Z, Fortina P, Patel P, Addya S, Surrey S, Acheampong EA, Mukhtar M, Pomerantz RJ: **Ethanol potentiates HIV-1 gp120-induced apoptosis in human neurons via both the death receptor and NMDA receptor pathways.** *Virology* 2005, **334**:59-73.
 49. Arokium H, Kamata M, Chen I: **Virion-associated Vpr of HIV-1 triggers the activation of apoptotic events and enhances Fas induced apoptosis in human T cells.** *J Virol* 2009.
 50. Sasaki Y, Ami Y, Nakasone T, Shinohara K, Takahashi E, Ando S, Someya K, Suzaki Y, Honda M: **Induction of CD95 ligand expression on T lymphocytes and B lymphocytes and its contribution to apoptosis of CD95-up-regulated CD4+ T lymphocytes in macaques by infection with a pathogenic simian/human immunodeficiency virus.** *Clin Exp Immunol* 2000, **122**:381-9.
 51. Iida T, Ichimura H, Shimada T, Ibuki K, Ui M, Tamaru K, Kuwata T, Yonehara S, Imanishi J, Hayami M: **Role of apoptosis induction in both peripheral lymph nodes and thymus in progressive loss of CD4+ cells in SHIV-infected macaques.** *AIDS Res Hum Retroviruses* 2000, **16**:9-18.
 52. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M: **Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection.** *Nature* 2005, **434**:1093-7.
 53. Li Q, Duan L, Estes JD, Ma ZM, Rourke T, Wang Y, Reilly C, Carlis J, Miller CJ, Haase AT: **Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells.** *Nature* 2005, **434**:1148-52.
 54. Kader M, Wang X, Piatak M, Lifson J, Roederer M, Veazey R, Mattapallil JJ: **Alpha4(+beta7(hi)CD4(+)) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection.** *Mucosal Immunol* 2009, **2**:439-49.
 55. Arnoult D, Petit F, Lelievre JD, Lecossier D, Hance A, Monceaux V, Hurtrel B, Ho Tsong Fang R, Ameisen JC, Estaquier J: **Caspase-dependent and -independent T-cell death pathways in pathogenic simian immunodeficiency virus infection: relationship to disease progression.** *Cell Death Differ* 2003, **10**:1240-52.
 56. Viollet L, Monceaux V, Petit F, Ho Tsong Fang R, Cumont MC, Hurtrel B, Estaquier J: **Death of CD4+ T cells from lymph nodes during primary SIVmac251 infection predicts the rate of AIDS progression.** *J Immunol* 2006, **177**:6685-94.
 57. Li Q, Smith AJ, Schacker TW, Carlis JV, Duan L, Reilly CS, Haase AT: **Microarray analysis of lymphatic tissue reveals stage-specific, gene expression signatures in HIV-1 infection.** *J Immunol* 2009, **183**:1975-82.
 58. Wallace M, Waterman PM, Mitchen JL, Djavani M, Brown C, Trivedi P, Horejsh D, Dykhuizen M, Kitabwalla M, Pauza CD: **Lymphocyte activation during acute simian/human immunodeficiency virus SHIV(89.6PD) infection in macaques.** *J Virol* 1999, **73**:10236-44.
 59. Aillet F, Masutani H, Elbim C, Raoul H, Chene L, Nugeyre MT, Paya C, Barre-Sinoussi F, Gougerot-Pocidal MA, Israel N: **Human immunodeficiency virus induces a dual regulation of Bcl-2, resulting in persistent infection of CD4(+) T- or monocytic cell lines.** *J Virol* 1998, **72**:9698-705.
 60. Fernandez Larrosa PN, Croci DO, Riva DA, Bibini M, Luzzi R, Saracco M, Mersich SE, Rabinovich GA, Martinez Peralta L: **Apoptosis resistance in HIV-1 persistently-infected cells is independent of active viral replication and involves modulation of the apoptotic mitochondrial pathway.** *Retrovirology* 2008, **5**:19.
 61. Badley AD, Dockrell DH, Algeciras A, Ziesmer S, Landay A, Lederman MM, Connick E, Kessler H, Kuritzkes D, Lynch DH, et al.: **In vivo analysis of Fas/FasL interactions in HIV-infected patients.** *J Clin Invest* 1998, **102**:79-87.
 62. Chavan SJ, Tamma SL, Kaplan M, Gersten M, Pahwa SG: **Reduction in T cell apoptosis in patients with HIV disease following antiretroviral therapy.** *Clin Immunol* 1999, **93**:24-33.
 63. Nishihara T, Ushio Y, Higuchi H, Kayagaki N, Yamaguchi N, Soejima K, Matsuo S, Maeda H, Eda Y, Okumura K, et al.: **Humanization and epitope mapping of neutralizing anti-human Fas ligand monoclonal antibodies: structural insights into Fas/Fas ligand interaction.** *J Immunol* 2001, **167**:3266-75.
 64. Salvato MS, Yin CC, Yagita H, Maeda T, Okumura K, Tikhonov I, Pauza CD: **Attenuated disease in SIV-infected macaques treated with a monoclonal antibody against FasL.** *Clin Dev Immunol* 2007, **2007**:93462.
 65. Poonia B, Salvato MS, Yagita H, Maeda T, Okumura K, Pauza CD: **Treatment with anti-FasL antibody preserves memory lymphocytes and virus-specific cellular immunity in macaques challenged with simian immunodeficiency virus.** *Blood* 2009.
 66. Villinger F, Folks TM, Lauro S, Powell JD, Sundstrom JB, Mayne A, Ansari AA: **Immunological and virological studies of natural SIV infection of disease-resistant nonhuman primates.** *Immunol Lett* 1996, **51**:59-68.
 67. Silvestri G, Sadora DL, Koups RA, Paiardini M, O'Neil SP, McClure HM, Staprans SI, Feinberg MB: **Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia.** *Immunity* 2003, **18**:441-52.

68. Yin C, Wu MS, Pauza CD, Salvato MS: **High major histocompatibility complex-unrestricted lysis of SIV envelope-expressing cells predisposes macaques to rapid AIDS progression.** *J Virol* 1999, **73**:3692-3701.
69. Monceaux V, Estaquier J, Fevrier M, Cumont MC, Riviere Y, Aubertin AM, Ameisen JC, Hurtrel B: **Extensive apoptosis in lymphoid organs during primary SIV infection predicts rapid progression towards AIDS.** *Aids* 2003, **17**:1585-96.
70. Meythaler M, Martinot A, Wang Z, Pryputniewicz S, Kasheta M, Ling B, Marx PA, O'Neil S, Kaur A: **Differential CD4+ T-lymphocyte apoptosis and bystander T-cell activation in rhesus macaques and sooty mangabeys during acute simian immunodeficiency virus infection.** *J Virol* 2009, **83**:572-83.
71. Vieillard V, Le Grand R, Dausset J, Debre P: **A vaccine strategy against AIDS: an HIV gp41 peptide immunization prevents NKp44L expression and CD4+ T cell depletion in SHIV-infected macaques.** *Proc Natl Acad Sci USA* 2008, **105**:2100-4.
72. Geiben-Lynn R, Greenland JR, Frimpong-Boateng K, van Rooijen N, Hovav AH, Letvin NL: **CD4+ T lymphocytes mediate in vivo clearance of plasmid DNA vaccine antigen expression and potentiate CD8+ T-cell immune responses.** *Blood* 2008, **112**:4585-90.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

